Aurobindo Pharma gets USFDA nod for generic of Pfizer's Revatio
New Delhi: Aurobindo Pharma today received final approval from the USFDA to manufacture and market generic version of Pfizer's Revatio (sildenafil citrate) tablets used in the treatment of high blood pressure in lungs."The company has received final approval from the US Food & Drug Administration (USFDA) to manufacture and market Sildenafil Tablets, 20 mg", Aurobindo Pharma said in a...
Login or Register to read the full article
New Delhi: Aurobindo Pharma today received final approval from the USFDA to manufacture and market generic version of Pfizer's Revatio (sildenafil citrate) tablets used in the treatment of high blood pressure in lungs.
"The company has received final approval from the US Food & Drug Administration (USFDA) to manufacture and market Sildenafil Tablets, 20 mg", Aurobindo Pharma said in a BSE filing.
The product is expected to be launched in the fourth quarter of the current fiscal, the statement said.
"The approved Abbreviated New Drug Application (ANDA) is bioequivalent and therapeutically equivalent to Pfizer's Revatio Tablets 20 mg", the company added.
Sildenafil Tablets are used in the treatment of pulmonary arterial hypertension (high blood pressure in the lungs).
Quoting IMS data, Aurobindo Pharma said the approved product has an estimated market size of USD 80 million for the twelve months ended September 2015.
This is the 51st ANDA to be approved out of Unit VII formulation facility in Hyderabad for manufacturing Oral Non-Antibiotic products, the company added.
Aurobindo now has a total of 219 ANDA approvals from the USFDA.
"The company has received final approval from the US Food & Drug Administration (USFDA) to manufacture and market Sildenafil Tablets, 20 mg", Aurobindo Pharma said in a BSE filing.
The product is expected to be launched in the fourth quarter of the current fiscal, the statement said.
"The approved Abbreviated New Drug Application (ANDA) is bioequivalent and therapeutically equivalent to Pfizer's Revatio Tablets 20 mg", the company added.
Sildenafil Tablets are used in the treatment of pulmonary arterial hypertension (high blood pressure in the lungs).
Quoting IMS data, Aurobindo Pharma said the approved product has an estimated market size of USD 80 million for the twelve months ended September 2015.
This is the 51st ANDA to be approved out of Unit VII formulation facility in Hyderabad for manufacturing Oral Non-Antibiotic products, the company added.
Aurobindo now has a total of 219 ANDA approvals from the USFDA.
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd